Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Public ClinicalTrials.gov record NCT02226120. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug. The parent PARADIGM-HF (NCT01035255) trial was terminated early due to compelling efficacy of LCZ696 in patients with heart failure with reduced ejection fraction (HFrEF) after the final pre-specified interim analysis in March 2014.
Study identification
- NCT ID
- NCT02226120
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,980 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2014
- Primary completion
- Dec 27, 2017
- Completion
- Dec 27, 2017
- Last update posted
- Feb 19, 2019
2014 – 2017
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Huntsville | Alabama | 35801 | — |
| Novartis Investigative Site | Muscle Shoals | Alabama | 35662 | — |
| Novartis Investigative Site | Little Rock | Arkansas | 72204 | — |
| Novartis Investigative Site | Oceanside | California | 92056 | — |
| Novartis Investigative Site | Palm Springs | California | 92262 | — |
| Novartis Investigative Site | San Diego | California | 92161 | — |
| Novartis Investigative Site | Santa Rosa | California | 95405 | — |
| Novartis Investigative Site | Boynton Beach | Florida | 33472-2952 | — |
| Novartis Investigative Site | Des Moines | Iowa | 50314 | — |
| Novartis Investigative Site | Covington | Louisiana | 70433 | — |
| Novartis Investigative Site | Columbia | Maryland | 21044 | — |
| Novartis Investigative Site | Saginaw | Michigan | 48601 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55417 | — |
| Novartis Investigative Site | Fremont | Nebraska | 68025 | — |
| Novartis Investigative Site | New York | New York | 10032 | — |
| Novartis Investigative Site | Rosedale | New York | 11422 | — |
| Novartis Investigative Site | Raleigh | North Carolina | 27610 | — |
| Novartis Investigative Site | Marion | Ohio | 43302 | — |
| Novartis Investigative Site | Rapid City | South Dakota | 57701 | — |
| Novartis Investigative Site | Dallas | Texas | 75235 | — |
| Novartis Investigative Site | Dallas | Texas | 75251 | — |
| Novartis Investigative Site | Livingston | Texas | 77351 | — |
| Novartis Investigative Site | Spokane | Washington | 99204 | — |
| Novartis Investigative Site | Waukesha | Wisconsin | 53188 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 370 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02226120, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2019 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02226120 live on ClinicalTrials.gov.